Twin-exenatide Study
- Conditions
- Adult patients with type 2 diabetes mellitus
- Registration Number
- JPRN-jRCTs031180320
- Lead Sponsor
- Itoh Hiroshi
- Brief Summary
Switching from exenatide BID to exenatide QW resulted in reduction in HbA1c, FPG and incidence of hypoglycemia and improvement in beta cell function and treatment satisfaction in patients with T2DM. These findings will be useful for selecting optimal treatment in individuals with T2DM.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 62
(1) Adult patients with type 2 diabetes mellitus (over 20 years of age)
(2) Patients treated with Byetta (over 12 weeks) (combined use of sulphonylurea, biguanide and/or thiazolidinedione is permissible)
(3) Patients from whom written informed consent for participation is obtained.
(1) Patients with type 1 diabetes mellitus,
(2) Patients with diabetic ketoacidosis
(3) Patients with diabetic coma and pre-coma
(4) Patients with history of serious hypersensitivity to exenatide or any of its components
(5)Patients who intend to become pregnant, and patients who are pregnant, parturient or lactating
(6) Patients with severe infections
(7) Patients at emergency surgery
(8) Patients with severe renal dysfunction, and patients on dialysis
(9) Any other condition which the attending physician feels would interfere with trial participation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in HbA1c level at week 24
- Secondary Outcome Measures
Name Time Method